

Delayed compared with early feeding in the initial hospital management of hyperemesis gravidarum

Submission date 14/03/2016	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 16/03/2016	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 20/05/2020	Condition category Pregnancy and Childbirth	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Nausea and vomiting are common symptoms during early pregnancy, occurring in about 70–85% of pregnancies. Some pregnant women experience excessive nausea and vomiting, known as hyperemesis gravidarum, which leads to dehydration and significant weight loss. Hospitalisation is typically needed to rehydrate patients through a drip and to control nausea and vomiting with medication. In hyperemesis gravidarum, nausea may be triggered by just the thought of food, and vomiting often follows drinking or eating. In women recently hospitalised for hyperemesis it is not known whether there is benefit to a short (12 hour) delay in eating and drinking to allow rehydration and medication to take effect before eating and drinking is restarted. On the other hand, continuing to feed at the same time as rehydration and medication may permit the quickest recovery path. The aim of this study is to find out which is the better approach.

Who can participate?

Pregnant women aged 18 or over with hyperemesis gravidarum

What does the study involve?

Participants are randomly allocated to one of two groups. One group is encouraged eat and drink as soon as possible after hospitalisation. The other group is told to delay eating and drinking (fast) for the first 12 hours after hospitalisation, then resume eating and drinking at their own pace. Both groups receive intravenous rehydration (a drip), thiamine (vitamin) supplementation and anti-emetic (anti- vomiting) medication as standard inpatient treatment for hyperemesis gravidarum. Frequency of vomiting, nausea, patient satisfaction and duration of hospitalisation are measured.

What are the possible benefits and risks of participating?

We do not foresee any major benefits or significant risks. It is not clear which intervention will prove to be superior and there is a distinct likelihood the interventions may produce similar outcomes.

Where is the study run from?
University Malaya Medical Centre (Malaysia)

When is the study starting and how long is it expected to run for?
April 2016 to September 2017

Who is funding the study?
University of Malaya (Malaysia)

Who is the main contact?
Prof. Peng Chiong Tan
pctan@um.edu.my

Contact information

Type(s)
Public

Contact name
Prof Peng Chiong Tan

Contact details
Department of Obstetrics and Gynaecology
Faculty of Medicine
University of Malaya
Lembah Pantai
Kuala Lumpur
Malaysia
50603
+60 (0)123 052 970
pctan@um.edu.my

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
1206.12

Study information

Scientific Title
Delayed compared with early oral intake in the initial management of hyperemesis gravidarum:
a randomised trial

Study objectives

An initial 12-hour period of fasting (delayed oral intake) at hospitalisation for hyperemesis gravidarum to allow for hydration and anti-emetic medication to become effective compared to early feeding will result in less nausea and vomiting and higher patient satisfaction at 24 hours.

Ethics approval required

Old ethics approval format

Ethics approval(s)

University Malaya Medical Centre Medical Ethics Committee, 04/02/2016, approval no. 1206.12

Study design

Two-arm clinical trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use then contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Hyperemesis gravidarum

Interventions

Participants are randomized to:

1. Delayed oral intake (fasting) for the first 12 hours after hospitalisation for hyperemesis gravidarum followed by resumption of taking fluids and solids orally at the participants own pace
2. Encouraged to take fluids and solids orally as soon as, as much as and as often as tolerated after hospitalisation for hyperemesis gravidarum

Both arms are to receive intravenous rehydration, oral thiamine supplementation and intravenous anti-emetic as standard inpatient treatment for hyperemesis gravidarum

Intervention Type

Behavioural

Primary outcome measure

1. Frequency of vomiting in the first 24 hours
2. Nausea score (using a Visual Numerical Rating Scale from 0 to 10) at enrollment, 8, 16 and 24 hours
3. Patient's satisfaction score (using a Visual Numerical Rating Scale from 0 to 10) at 24 hours

Secondary outcome measures

1. Duration of hospitalisation
2. Ketonuria at 24 hours
3. An 8-item symptoms questionnaire at 24 hours
4. Participant preference on feeding regimen in a future hospitalisation for hyperemesis gravidarum at 24 hours
5. Participant recommendation of their feeding regimen to a friend in the same circumstances at 24 hours

Overall study start date

01/04/2016

Completion date

30/09/2017

Eligibility**Key inclusion criteria**

1. Clinical diagnosis of hyperemesis gravidarum
2. First hospitalisation for hyperemesis gravidarum in current pregnancy
3. Presence of ketonuria by urine dipstick (of 2+ or greater) at hospitalisation
4. At least 18 years of age
5. Pregnancy gestation of 14 weeks or less

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Female

Target number of participants

160

Total final enrolment

160

Key exclusion criteria

1. Multiple pregnancy
2. Molar pregnancy
3. Confirmed non-viable pregnancy
4. Any medical condition that contraindicates oral feeding or fasting

Date of first enrolment

01/04/2016

Date of final enrolment

30/09/2017

Locations

Countries of recruitment

Malaysia

Study participating centre

University Malaya Medical Centre

Jalan Universiti

Kuala Lumpur

Malaysia

50603

Sponsor information

Organisation

University of Malaya (Malaysia)

Sponsor details

Lembah Pantai

Kuala Lumpur

Malaysia

50603

Sponsor type

University/education

ROR

<https://ror.org/00rzspn62>

Funder(s)

Funder type

University/education

Funder Name

Universiti Malaya

Alternative Name(s)

University of Malaya, University Malaya, Malayan University, UM

Funding Body Type

Government organisation

Funding Body Subtype

Universities (academic only)

Location

Malaysia

Results and Publications

Publication and dissemination plan

We plan to publish the trial results. We are not planning to release raw trial data.

Intention to publish date

30/09/2018

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	30/04/2020	20/05/2020	Yes	No